GlassScriptPhysician profile
John S Prichard
NPI 1457389850
$5,291.02
in general payments reported to CMS, 2019-2025
10 companies · $99.82 in 2025
The $99.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,705 · 2021: $36.22 · 2022: $141 · 2023: $168 · 2024: $141 · 2025: $99.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $4,587.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $232.25 | 2021-2023 | Pomalyst |
| Amgen INC. | $117.08 | 2019 | |
| Janssen Biotech, INC. | $112.57 | 2021-2025 | Rybrevant, Carvykti |
| Pfizer INC. | $105.86 | 2024 | |
| Gilead Sciences, INC. | $38.56 | 2023-2024 | |
| Celgene Corporation | $28.05 | 2023 | Reblozyl |
| Genmab U.S., INC. | $24.99 | 2023 | Epkinly |
| Alcon Vision LLC | $23.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Prichard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.